丙型肝炎病毒基因型与慢性丙型肝炎患者预后的相关性研究  

Study on Relationship between HCV Genotypes and Prognosis of HCV Patients

作　　者：唐先梅[1] 董玉虹[2] 

机构地区：[1]汉中市中心医院感染科,汉中723000 [2]青岛市传染病医院肝病四区,青岛266000

出　　处：《成都医学院学报》2015年第4期397-399,共3页Journal of Chengdu Medical College

基　　金：中国高校医学期刊临床专项资金(No:11523061)

摘　　要：目的探讨丙型肝炎(HCV)病毒基因型与慢性HCV患者经抗病毒治疗实现持续病毒学应答(sustained virological response,SVR)之间的关系。方法选取慢性HCV患者45例,根据治疗后患者是否实现SVR分为SVR组(n=14)和非SVR组(n=31)。采用线性探针反向杂交法(INNO-LiPA)检测HCV基因型,两组患者经聚乙二醇干扰素(PEG-IFN)联合利巴韦林(RBV)治疗后检测SVR,分析HCV基因型与SVR之间的相关性。结果非SVR组中HCV基因1型患者显著多于SVR组,差异具有统计学意义(P<0.05);HCV基因型与PEG-IFN联合RBV治疗响应有显著相关性,HCV基因2、3型是与治疗反应相关的最强因素,且独立于其他变量之外,差异具有统计学意义(P<0.05)。结论 HCV基因型是慢性HCV感染患者经PEG-IFN联合RBV治疗预后的一个重要独立预测因素,可用于患者最佳抗病毒治疗方案的选择。Objective To explore the relationship between HCV （hepatitis C virus） genotypes and prognosis of chronic HCV patients after treatment with PEG-IFN （pegylated interferons） combined with RBV（ribavirin）. Methods A total of 45 HCV patients were divided into SVR（sustained virological response） group （n= 14） and non-SVR group （n=31）. A line probe assay （INNO-LiPA） was used to detect HCV genotypes and determine SVR after treatment with PEC^IFN combined with RBV so as to analyze the relationships between HCV genotypes and SVR. Results The number of patients with HCV genotype 1 was evidently higher in non-SVR group than in SVR group, the difference of which was statically significant （P〈0.05）. HCV genotypes were in significant association with the responses to treatment with PEG-IFN combined with RBV while HCV genotypes 2 and 3 were the strongest genes related with therapeutic responses and were independent of other variables （P〈0.05）. Conclusion HCV genotype is an important independent predictive factor for the prognosis of chronic HCV patients after treated with PEG-IFN combined with RBV. Therefore, it can be used as the optimal therapeutic protocol in anti-virus therapies.

关 键 词：丙型肝炎 聚乙二醇干扰素 利巴韦林 病毒基因型 

分 类 号：R512.63[医药卫生—内科学]